NextPoint Therapeutics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
NextPoint Therapeutics is a clinical-stage immuno-oncology company targeting the HHLA2 checkpoint with two Phase 1 candidates (NPX267, NPX887); raised $122.5M total including $42.5M Series B extension co-led by Catalio in 2024.
About
NextPoint Therapeutics is a clinical-stage biotechnology company developing precision immuno-oncology therapeutics that target the HHLA2 (B7-H7) immune checkpoint pathway. HHLA2 is a novel checkpoint ligand that suppresses anti-tumor T cell and NK cell activity in many solid tumors independently of PD-L1, providing a rationale for combination with existing checkpoint inhibitors or as a monotherapy in PD-L1-resistant tumors.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Also Compare
NextPoint Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.